You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME/CE

Safe Prescribing for Pain

  • Authors: Gayathri Dowling, PhD; Richard A. Denisco, MD
  • CME/CE Released: 9/26/2012; Reviewed and Renewed: 10/2/2014
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/2/2015
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care clinicians, neurologists, anesthesiologists, pain specialists, obstetrician/gynecologists, orthopedists, nurse practitioners, nurses and other healthcare practitioners who manage patients with chronic pain.

The goal of this activity is to describe the prevalence of prescription opioid abuse in the United States and the skills and tools clinicians can use to screen for and prevent abuse in patients with pain.

Upon completion of this activity, participants will be able to:

  1. Communicate effectively with patients regarding opioid use and abuse
  2. Use appropriate opportunities to screen for drug use, including nonmedical use of prescription drugs
  3. Evaluate patient risk for opioid pain medication abuse through screening and monitoring
  4. Recognize the extent and potential for abuse of prescription opioids
  5. Employ prescribing practices that support safe use of prescription opioids


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Gayathri Dowling, PhD

    Acting Chief, Science Policy Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

    Disclosures

    Disclosure: Gayathri Dowling, PhD, has disclosed no relevant financial relationships.

    Dr Dowling does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Dowling does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Richard A. Denisco, MD

    Medical Officer, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

    Disclosures

    Disclosure: Richard A. Densico, MD, has disclosed no relevant financial relationships.

    Dr Denisco does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Denisco does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Jane Lowers

    Group Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Jane Lowers has disclosed no relevant financial relationships.

  • Neil Chesanow

    Senior Clinical Editor, Medscape, LLC

    Disclosures

    Disclosure: Neil Chesanow has disclosed no relevant financial relationships.

Writer(s)

  • Lynne Kolton Schneider, PhD

    Freelance writer, Boca Raton, Florida

    Disclosures

    Disclosure: Lynne Kolton Schneider, PhD, has disclosed no relevant financial relationships.

Additional Planners/Reviewer(s)

  • Robert Carroll, PhD, RN

    Project director, IQ Solutions, Rockville, MD

    Disclosures

    Disclosure: Robert Carroll, PhD, RN, has disclosed no relevant financial relationships.

  • Denise Crute, MA

    Director of training, IQ Solutions, Rockville, MD

    Disclosures

    Disclosure: Denise Crute, MA has disclosed no relevant financial relationships.

  • Bill H. McCarberg, MD

    Primary Care Physician, Adjunct Assistant Clinical Professor, University of California, San Diego; Founder, Chronic Pain Management Program, Kaiser Permanente, San Diego, California

    Disclosures

    Disclosure: Bill McCarberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: PriCara; Forest Laboratories, Inc.; Endo Pharmaceuticals; Sucampo Pharmaceuticals, Inc.; NeurogesX, Inc.; Teva Pharmaceuticals; Insys Therapeutics, Inc; QRX Pharma Ltd; Salix Pharmaceuticals, Inc.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner(s)

  • Laurie E. Scudder, DNP, NP

    Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME/CE

Safe Prescribing for Pain

Authors: Gayathri Dowling, PhD; Richard A. Denisco, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME/CE Released: 9/26/2012; Reviewed and Renewed: 10/2/2014

Valid for credit through: 10/2/2015

processing....

Abbreviations

COMM = Current Opioid Misuse Measure
ED = emergency department
FDA = Food and Drug Administration
NIDA = National Institute on Drug Abuse
NM ASSIST = NIDA-modified Alcohol, Smoking, and Substance Involvement Screening Test
ONDCP = Office of National Drug Control Policy
ORT = Opioid Risk Tool
PADT = Pain Assessment and Documentation Tool
PDMP = Prescription drug monitoring program
PI = patient information
SOAPP = Screener and Opioid Assessment for Patients With Pain

« Return to: Safe Prescribing for Pain
  • Print